Two cardiometabolic-related news items have been observed: Nemaura Medical published its CY Q4 ’20 (FY Q3 ’21) earnings update and Metacrine announced the results of the MET409 proof-of-concept study were published in the Journal of Hepatology. Below, FENIX provides highlights and insights for the respective news items.
Two diabetes-related news items have been observed: Senseonics announced its partner, Ascensia, has reinitiated EU commercial activities for the Eversense XL implantable CGM system; and Nemaura Medical announced the appointment of Jay Warner as Head of US Commercial Operations. Below, FENIX provides highlights and insights for the respective news items, including the curious mention of Livongo in the Nemaura press release.
Nemaura announced the US launch of its BEATdiabetes program and proBEAT non-invasive CGM. Recall, Nemaura’s non-invasive sugarBEAT CGM was originally filed under the wellness category (and launched in the US as proBEAT) for people with T2DM and prediabetes as part of the BEATdiabetes platform. A PMA has been filed for sugarBEAT and Nemaura anticipates FDA approval and a US launch by YE ’21. Below, FENIX provides brief insight on the BEATdiabetes launch in the context of Nemaura as an acquisition target.
Three diabetes-related news items have been observed: BI and Lilly announced results from a post hoc analysis of the EMPA-REG OUTCOME trial; Abbott and ADA announced Abbott is the first anchor sponsor of the Health Equity Now (HEN) platform with a $5M contribution towards addressing health disparities for PWD; and Nemaura Medical announced the relaunch of its company website and the launch of its BEAT diabetes website. Below, FENIX provides highlights and insights for the respective news items.
A series of diabetes-related news items have been observed: Dicerna announced FDA accepted Lilly’s IND application for a novel, unknown cardiometabolic asset, LY3561774; Gilead and Novo Nordisk announced positive results from a Ph2 PoC trial evaluating Novo’s semaglutide in combination with Gilead’s investigational FXR agonist and/or its ACC inhibitor for the treatment of NASH; Biocorp announced the launch of its Mallya insulin connected cap in Europe via a partnership with cgmDiabet; Nemaura Medical announced its CY Q3 ’20 (FY Q2 ’21) earnings; and Diabeloop and Terumo Corporation announced a partnership for the joint development of an AID system and exclusive distribution rights in Japan. Below, FENIX provides highlights and insight for the respective news items including curious questions on the Dicerna target split between Lilly-Novo and semaglutide Ph3 combos in NASH.